Alogliptin possibly more effective than glipizide for type 2

A two year clinical trial has found alogliptin to be a more effective drug for type 2 diabetes patients with inadequate glycaemic control compared with sulphnylurea (SU) glipizide.

The study randomised 2,639 patients aged 18 to 80 years to 104 weeks of treatment with metformin in addition to either alogliptin 12.5mg, alogliptin 25mg or glipizide 5mg.

At the end of the study, 45.6% of alogliptin 12.5mg patients and 48.5% of alogliptin 25mg had HbA1c levels of 7% or below,